## Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, o1/o9/99, o1/o7/o0, 30/o9/o1, 11/o3/o2, o1/o1/o3, 24/10/o5, o1/o8/12, o1/o1/o2, o1/o1/o3, o1/$ 

Kog	gi Iron Limited	
ABN		
28 (	001 894 033	
We	(the entity) give ASX the follow	ing information.
	t 1 - All issues must complete the relevant sections (at	tach sheets if there is not enough space).
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	Ordinary fully paid shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	20,000,000 Ordinary Shares
3	Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Ordinary Shares will rank pari passu with existing Ordinary Shares

Name of entity

<sup>+</sup> See chapter 19 for defined terms.

Do the \*securities rank equally in all Ordinary Shares will rank pari passu with respects from the date of allotment existing Ordinary Shares with an existing +class of quoted \*securities? If the additional securities do not rank equally, please state: the date from which they do extent to which they participate for the next dividend, the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Issue price or consideration \$2,000,000 The purpose of the issue of Ordinary shares is to raise Purpose of the issue (If issued as consideration for the funds for testwork programs for the Agbaja project, acquisition of assets, clearly identify executive recruitment and salary costs, in-country those assets) costs and to provide working capital. Is the entity an +eligible entity that Yes has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder resolution 21 November 2017 under rule 7.1A was passed Number of \*securities issued without 20,000,000 security holder approval under rule 7.1 6d Number of \*securities issued with Nil security holder approval under rule 7.1A

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of securities issued under an exception in rule 7.2	n/a	
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	n/a	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	n/a	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1: 46,013,982 7.1A: 58,884,232	
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	9 February 2018	
		Number	<sup>+</sup> Class
8	Number and *class of all *securities quoted on ASX ( <i>including</i> the securities in section 2 if applicable)	611,154,685	Ordinary Shares

<sup>+</sup> See chapter 19 for defined terms.

		Number	<sup>+</sup> Class
9	Number and +class of all +securities	1,000,000	Ordinary Shares subject to
	not quoted on ASX (including the		vesting conditions pursuant to
	securities in section 2 if applicable)		the Company Loan Share Plan
		29,800,000	Unlisted Options with an
			exercise price of \$0.0305 expiring
			16 <sup>th</sup> November 2019.
10	Dividend policy (in the case of a	N/a	
	trust, distribution policy) on the		
	increased capital (interests)		
Dart	2. Popus issue or pro rata i	CCIIO	
ган	2 - Bonus issue or pro rata i	SSUC	
	1	/-	
11	Is security holder approval required?	n/a	
	Is the four monomorphic on mon	/-	
12	Is the issue renounceable or non-renounceable?	n/a	
	renounceable:		
12	Ratio in which the *securities will be	n/a	
13	offered	11/ d	
	onered		I
1.4	*Class of *securities to which the	n/a	
14	offer relates	11/ a	
	oner relates		l
15	<sup>+</sup> Record date to determine	n/a	
15	entitlements	11/α	
	Cherencines		
16	Will holdings on different registers	n/a	
10	(or subregisters) be aggregated for	π, α	
	calculating entitlements?		
	o de la companya de		
17	Policy for deciding entitlements in	n/a	
-/	relation to fractions	11/ 4	
18	Names of countries in which the	n/a	
	entity has *security holders who will		
	not be sent new issue documents		

Note: Security holders must be told how their entitlements are to be dealt with.

Cross reference: rule 7.7.

19	Closing date for receipt of acceptances or renunciations	n/a
20	Names of any underwriters	n/a
21	Amount of any underwriting fee or commission	n/a
22	Names of any brokers to the issue	n/a
23	Fee or commission payable to the broker to the issue	n/a
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	n/a
25	If the issue is contingent on *security holders' approval, the date of the meeting	n/a
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	n/a
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	n/a
28	Date rights trading will begin (if applicable)	n/a
29	Date rights trading will end (if applicable)	n/a
30	How do *security holders sell their entitlements in full through a broker?	n/a
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	n/a

<sup>+</sup> See chapter 19 for defined terms.

32	thei	w do <sup>+</sup> security holders dispose of r entitlements (except by sale ough a broker)?	n/a	
33	†De	spatch date	n/a	
		uotation of securities complete this section if you are applyin	ng for quotation of securities	
34	Type (tick o	of securities one)		
(a)		Securities described in Part 1		
(b)		All other securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities		
Entitie	es tha	t have ticked box 34(a)		
Addit	ional	securities forming a new cla	ss of securities	
Tick to docume		e you are providing the information o	r	
35			curities, the names of the 20 largest holders of the number and percentage of additional	
36		If the *securities are *equity secu**securities setting out the number 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over	urities, a distribution schedule of the additional er of holders in the categories	
37		A copy of any trust deed for the	additional <sup>+</sup> securities	

Appendix 3B Page 6 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

### Entities that have ticked box 34(b)

38	Number of securities for which <sup>+</sup> quotation is sought	n/a	
39	Class of *securities for which quotation is sought	n/a	
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?	n/a	
	If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation	n/a	
41	now	11/α	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
42	Number and *class of all *securities quoted on ASX (including the securities in clause 38)	Number	<sup>+</sup> Class

<sup>+</sup> See chapter 19 for defined terms.

#### Quotation agreement

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before <sup>†</sup>quotation of the <sup>†</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 9 February 2018

(Director/Company Secretary)

Print name: Kevin Hart

== == == ==

Appendix 3B Page 8 o1/08/2012

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities

Introduced 01/08/12

### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	478,972,774	
Add the following:		
Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2	-	
Number of fully paid ordinary securities issued in that 12 month period with shareholder approval	109,869,545	
Number of partly paid ordinary securities that became fully paid in that 12 month period	Nil	
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
Subtract the number of fully paid ordinary securities cancelled during that 12 month period	Nil	
"A"	588,842,319	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15	88,326,348	
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule	
<ul> <li>Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:</li> <li>Under an exception in rule 7.2</li> <li>Under rule 7.1A</li> <li>With security holder approval under rule 7.1 or rule 7.4</li> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	2,312,366 (15 November 2017) 20,000,000 (Options issued 29 December 2017) 20,000,000 (9 February 2018)	
"C"	42,312,366	
Step 4: Subtract "C" from ["A" x "I placement capacity under rule 7.1 "A" x 0.15 Note: number must be same as shown in Step 2	B"] to calculate remaining 88,326,348	
Subtract "C"  Note: number must be same as shown in Step 3	42,312,366	
<i>Total</i> ["A" x 0.15] – "C"	46,013,982  [Note: this is the remaining placement capacity under rule 7.1]	

### Part 2

Appendix 3B Page 10 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A" 588,842,319		
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	58,884,232	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<b>Insert</b> number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A		
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"E"	-	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A			
"A" x 0.10	58,884,232		
Note: number must be same as shown in Step 2			
Subtract "E"	-		
Note: number must be same as shown in Step 3			
<b>Total</b> ["A" x 0.10] – "E"	58,884,232		
	Note: this is the remaining placement capacity under rule 7.1A		

Appendix 3B Page 12 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.





Solse

9 February 2018

### Notice Under Section 708A(5)(e) of the Corporations Act

Kogi Iron Limited (ASX: KFE – the "Company" or "Kogi") today issued and allotted 20,000,000 fully paid ordinary shares ("Securities") as a private placement to sophisticated investors at 10 cents per share to raise \$2,000,000 (before costs), as announced on 5 February 2018.

#### **Secondary Trading Exemption:**

The Corporations Act 2001 (Cth) (the "Act") restricts the on-sale of securities issued without disclosure, unless the sale is exempt under Section 708 or 708A of the Act. By the Company giving this notice, a sale of the Securities noted above will fall within the exemption in section 708A(5) of the Act.

The Company hereby notifies the ASX under paragraph 708(A)(5)(e) of the Act that:

- a) The Company issued the Securities without disclosure to investors under Part 6D.2 of the Act;
- b) As at the date of this notice the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company, and section 674 of the Act; and
- c) As at the date of this notice there is no information:
  - i) that has been excluded from a continuous disclosure notice in accordance with the Listing Rules; and
  - ii) that investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
    - (1) The assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
    - (2) The rights and liabilities attaching to the Securities.

Yours sincerely

**KOGI IRON LIMITED** 

**Kevin Hart** 

Company Secretary

**KFE Capital Summary** 

Ordinary Shares: 612,154,685 Unlisted options: 29.8m

Share price: \$0.13

Market capitalisation: \$80m

**Board of Directors** 

Dr Ian Burston – *Non Executive Chairman* Mr Kevin Joseph – *Executive Director* Mr Don Carroll – *Non Executive Director* 

Mr Michael Tilley – *Non Executive Director* Mr Martin Wood – *Managing Director*  **Contact** 

Unit 23, 4 Ventnor Avenue, West Perth WA 6005

Tel: +61 8 9200 3456 Email: info@kogiiron.com

W: www.kogiiron.com